文献速递皮肤肿瘤

BRAF融合基因驱动的先天性黑色素细胞痣伴坚实、瘙痒及促结缔组织增生间质

Congenital melanocytic naevi initiated by BRAF fusion oncogene with firmness, pruritus and desmoplastic stroma.
PubMed 文献 · Br J Dermatol · 2025-01-01

该研究回顾性分析了3家学术机构的5例携带BRAF融合基因的巨大先天性黑色素细胞痣(CMN)患者,采用捕获式二代测序分析肿瘤DNA。5例中4例有数千颗卫星痣,许多伴明显瘙痒、结节和坚实感;1例发生神经皮肤黑变病,组织病理示显著间质促结缔组织增生。1例对MEK抑制剂曲美替尼有应答,提示遗传学表征的治疗潜力。

要点

  • BRAF融合基因阳性的巨大CMN可表现为大量瘙痒性、结节性、坚实的卫星痣。
  • 显著间质促结缔组织增生是提示BRAF融合基因的组织病理学特征。
  • 对BRAF融合基因阳性的CMN患者,MEK抑制剂曲美替尼可能带来治疗获益。

核心结论

  • 携带BRAF融合基因的CMN具有独特临床特征,可伴大量卫星病灶。
  • 显著促结缔组织增生可提示 underlying BRAF融合基因。
  • BRAF融合基因阳性的CMN患者可能从特定靶向治疗中获益。

研究设计与样本

  • 回顾性研究,从3家学术机构识别5例携带BRAF融合基因的巨大CMN患者。
  • 采用捕获式二代测序分析肿瘤DNA。

主要发现

  • 5例中4例有数千颗卫星痣,许多伴明显瘙痒、结节和坚实感。
  • 1例发生神经皮肤黑变病。
  • 组织病理示显著间质促结缔组织增生,类似获得性黑色素细胞痣伴BRAF融合基因的改变。
  • 1例对MEK抑制剂曲美替尼有应答。

关键数值与推荐

  • 1例对MEK抑制剂曲美替尼有应答;原文未报告剂量或疗效数值。

临床怎么用

  • 对巨大CMN伴大量瘙痒性、结节性、坚实卫星痣的患者,应考虑BRAF融合基因检测。
  • 组织病理见显著促结缔组织增生时,可提示BRAF融合基因。
  • 对BRAF融合基因阳性的CMN患者,可评估MEK抑制剂曲美替尼的治疗可能性。

局限性

  • 回顾性研究,样本量仅5例,来自3家学术机构。
  • 原文未报告长期随访数据或对照比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Large and giant congenital melanocytic naevi (CMN) present a risk for developing melanoma or neurocutaneous melanosis. Most CMN are caused by NRAS or, less commonly, BRAF mutations. OBJECTIVES: To present a series of patients with large-to-giant CMN with BRAF fusion genes as driver alterations and describe their unique clinical presentation. METHODS: We retrospectively identified five patients, from three academic institutions, with giant CMN harbouring BRAF fusion genes. We analysed tumour DNA using capture-based next-generation sequencing. RESULTS: Four of five patients with giant CMN harbouring a BRAF fusion gene exhibited thousands of satellite naevi, many with significant pruritus, nodularity and firmness. One patient developed neurocutaneous melanosis. Histopathology showed marked stromal desmoplasia, akin to the changes observed in acquired melanocytic naevi with BRAF fusion genes. Notably, one patient responded to the MEK inhibitor trametinib, demonstrating the potential therapeutic advantage of genetic characterization of these lesions. CONCLUSIONS: CMN with BRAF fusion genes appear to have unique clinical features and may be associated with numerous satellite lesions. Marked desmoplasia is a histopathological feature that can point to an underlying BRAF fusion gene. Giant congenital melanocytic naevi (or ‘CMN’ for short) are rare, non-cancerous tumours that are present at birth. They are caused by genetic mutations. ‘Naevi’ are more commonly called moles. In this study, we looked at large and giant CMN in five patients with a rare genetic mutation. Some of these patients had many smaller coloured moles that became firm and itchy. This is an unusual presentation. Using special genetic techniques, we analysed DNA from the tumours. We found that four out of five of the patients with giant CMN and a genetic mutation in genes called ‘BRAF fusion genes’ had many other smaller moles (‘satellite naevi’) that were itchy, lumpy and hard. One patient developed a condition called ‘neurocutaneous melanosis’, where tumours form in the central nervous system. We also found other changes, including increased growth of certain tissues. Finally, we found that one of the patients benefited from being treated with a medicine called ‘trametinib’. Overall, our findings suggest that CMN caused by BRAF fusion genes could have unique features. They may also be associated with other satellite lesions on the body. An increase in the growth of some tissues could indicate an underlying mutation in a BRAF fusion gene. Our results show that people with CMN who have mutations in BRAF fusion genes may benefit from specific treatments.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Roy SF, Agim NG, Mir A, et al. Congenital melanocytic naevi initiated by BRAF fusion oncogene with firmness, pruritus and desmoplastic stroma. Br J Dermatol. 2025. PMID: 40036344. doi:10.1093/bjd/ljaf061

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。